New CagriSema results have renewed comparisons with tirzepatide. Learn why dose, diabetes status and trial design matter, and how to track your own treatment with Peptimize.
If you take a GLP-1 medicine, a headline announcing a new weight-loss “winner” can make your own treatment suddenly feel outdated. It is tempting to compare the largest percentage in a news story with the number on your scale and wonder whether you should be taking something else.
The renewed discussion about CagriSema versus tirzepatide is a good example of why that shortcut can mislead. A clinical trial answers a particular question about a particular treatment plan. It does not automatically rank every dose of two medicines for every person.
This article explains the latest comparison, how it fits with earlier evidence, and how to turn the news into useful questions for your prescriber. It also offers a practical way to organize your own dose history, symptoms and progress in Peptimize.
On September 21, Novo reported phase 3 topline findings from REIMAGINE 5. In adults with type 2 diabetes, CagriSema 1.0 mg/1.0 mg produced an estimated 12.4% weight reduction at 60 weeks, versus 9.1% with tirzepatide 5 mg. The weight endpoint favored CagriSema; HbA1c reductions were 1.71 and 1.67 percentage points, respectively, meeting non-inferiority. These figures used an efficacy estimand. [1]
A separate placebo-controlled trial, REDEFINE 9, reported 21.0% weight reduction with CagriSema 1.0 mg/1.0 mg versus 2.0% with placebo at 68 weeks in adults with overweight or obesity. That trial did not compare CagriSema with tirzepatide. [1]
CagriSema combines cagrilintide, an amylin receptor agonist, with semaglutide, a GLP-1 receptor agonist. It remains investigational. Novo says its weight-management application is under FDA review, with a decision expected in the fourth quarter of 2026. An expected decision is not an approval. [1]
In February 2026, Novo reported results from REDEFINE 4: an 84-week, open-label trial involving 809 adults with obesity and at least one comorbidity. It compared CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg. Estimated weight reductions assuming adherence were 23.0% and 25.5%, respectively. CagriSema did not meet the primary goal of demonstrating non-inferiority for weight loss. [2]
The treatment-regimen analysis, which assessed effects regardless of adherence, gave different estimates: 20.2% and 23.6%. Participants and investigators knew which medicine was being given because the trial was open-label. Those details belong alongside the headline numbers. [2]
The two comparisons do not ask the same question. A finding at one pair of doses cannot settle the comparison at another pair. Different populations, follow-up periods and analysis methods also make it inappropriate to treat separate studies as interchangeable contests.
A drug name without a dose leaves out an essential part of a trial result. Tirzepatide acts at GIP and GLP-1 receptors. For weight management, the US Zepbound label lists 5 mg, 10 mg and 15 mg as maintenance doses; 2.5 mg is the starting dose. Calling 5 mg merely a “starter dose” is inaccurate, even though it is below the maximum. The label directs clinicians to consider response and tolerability when choosing maintenance treatment. [3]
Milligrams also cannot be compared across different molecules as if they were a common strength scale. Two medicines with different receptor actions and pharmacology do not become equivalent simply because their numerical doses look similar.
Ask whether participants had type 2 diabetes, what other treatments they used and which eligibility criteria applied. A study population can differ from your own situation in several important ways. Even an excellent randomized trial is most directly informative about the people and treatment plans it actually studied.
For a personal appointment, the useful question is: “How closely does this population resemble me?” That invites a more meaningful discussion than asking whether a medicine is universally stronger.
A result after more than a year of treatment should not become a personal target for your first few months. The starting point, dose-escalation period and time at maintenance all matter. Comparing an early response with a late trial endpoint leaves out most of the treatment timeline.
Likewise, a percentage from one follow-up duration cannot simply be projected forward in a straight line. A trial endpoint describes what was assessed at that time; it does not promise that the same rate continues indefinitely.
An estimand defines the treatment effect a trial is trying to estimate. It includes how events such as stopping treatment or using additional therapies are handled. An analysis estimating results under continued treatment can answer a different question from one that includes outcomes regardless of adherence. FDA guidance emphasizes aligning the clinical question, estimand and analysis. [4]
Neither label automatically makes an estimate misleading. The problem comes when a reader compares unlike estimates without knowing it. Look for both the main analysis and supporting analyses, and ask how missing observations were addressed.
A weight-loss percentage cannot summarize the entire treatment experience. A full assessment also needs information about adverse events, discontinuation, dose changes, quality of life and the uncertainty around the estimated benefit.
“Non-inferior” also has a precise meaning: a study met a predefined statistical standard for ruling out an unacceptable disadvantage. It does not establish that two treatments are identical, and it does not automatically establish superiority for a different outcome.
The September release is a sponsor's topline announcement, not a full study report. It does not provide enough detail to independently assess every aspect of the comparison. [1]
When fuller results become available, useful questions include:
These questions are not reasons to dismiss a positive finding. They are how a promising result becomes evidence that clinicians can apply responsibly. Until the details are available, claims that one product is better tolerated or best for everyone go beyond what a weight-loss headline establishes.
A new trial announcement does not show that your current treatment has failed. Your clinician can review whether your treatment is meeting the goals you agreed on, how you are tolerating it and whether another approach is appropriate.
Before an appointment, try writing down the actual concern behind the headline. Is your weight trend different from what you expected? Are symptoms making daily life difficult? Is hunger returning? Have supply or cost interruptions made your routine inconsistent? Each question leads to a different conversation.
Do not add another GLP-1 medicine or attempt to recreate an investigational combination yourself. Zepbound's prescribing information advises against combining it with another tirzepatide product or a GLP-1 receptor agonist. Severe or persistent abdominal pain, repeated vomiting or symptoms suggesting dehydration warrant prompt medical assessment. [3]
Research can guide the conversation, but your own record helps make that conversation specific. Peptimize brings dose logging, weight trends, appetite entries, side effects and daily tracking into one place. A consistent record can help you describe what happened without relying on memory.
Log the prescribed medication, dose and date you actually took it. If your clinician changes the plan, keep a clear record of when the change happened. A missed or delayed dose is useful context to record honestly, rather than a gap to hide.
This makes it easier to distinguish “I have been on this medicine for three months” from “I have only been on the current prescribed dose for two weeks.” Those statements describe different timelines.
Use a consistent measurement routine agreed with your care team, and look at the weight trend over an appropriate period. Add context when an entry follows travel, illness or a disrupted routine. Avoid treating every daily movement as evidence that the medicine has become stronger or weaker.
Your log is not a clinical trial. It cannot establish what would have happened on a different medicine. Its purpose is to help you and your clinician understand the course of your actual treatment.
Peptimize's appetite tracking separates hunger, food noise and cravings. Recording them consistently can help you describe your experience more clearly than a broad statement such as “it stopped working.” Side-effect entries add another part of the picture.
For example, a hypothetical patient might report lower hunger but also nausea that repeatedly disrupts breakfast. That is a more useful observation to bring to a prescriber than focusing only on the amount of weight lost. The log shows timing; it does not prove what caused the symptoms.
Review your entries and prepare three points: what improved, what remains difficult and what you want help deciding. Peptimize's weekly view can support that review, alongside any clinical measurements or test results your care team already holds.
Peptimize supports record keeping. It does not choose a medicine, recommend a dose or decide when to switch treatment.
Before deciding that a trial changes everything, look for the population, dose, comparator, duration and analysis. Then consider the safety and discontinuation data alongside the benefits. If one of those pieces is missing, keep the conclusion appropriately narrow.
The practical next step is to connect the evidence with your own care. Keep a clear record, bring specific concerns to your clinician and let a treatment decision reflect both the research and your experience.
For educational purposes only. Treatment decisions should be made with a qualified healthcare professional. Trial doses are described to explain the research, not as instructions for personal use.
Educational content only. Nothing here is medical advice, a diagnosis, or a dosing or titration recommendation. Decisions about any medication belong with you and your prescriber.
